Protein tyrosine phosphatase receptor type C (PTPRC or CD45)

Maryam Ahmed Al Barashdi 1, Ahlam Ali 1, Mary Frances McMullin 2, Ken Mills 1

ABSTRACT
The leucocyte common antigen, protein tyrosine phosphatase receptor type C (PTPRC), also known as CD45, is a transmembrane glycoprotein, expressed on almost all haematopoietic cells except for mature erythrocytes, and is an essential regulator of T and B cell antigen receptor-mediated activation. Disruption of the equilibrium between protein tyrosine kinase and phosphatase activity (from CD45 and others) can result in immunodeficiency, autoimmunity, or malignancy. CD45 is normally present on the cell surface, therefore it works upstream of a large signalling network which differs between cell types, and thus the effects of CD45 on these cells are also different. However, it is becoming clear that CD45 plays an essential role in the innate immune system and this is likely to be a key area for future research. In this review of PTPRC (CD45), its structure and biological activities as well as abnormal expression of CD45 in leukaemia and lymphoma will be discussed.

INTRODUCTION
Despite thousands of publications and more than 50 years of research, CD45 physiology and biology requires to be clarified to answer questions on CD45 phosphatase activity (PTA) regulation, the role of extracellular domain of CD45, alternative splicing of exons, the function of CD45 isoforms and many others.

CD45 is an essential protein on the surface of cells of the haematological and immunological systems. It has been used as a diagnostic tool to identify cells of haematological origin, but its function and structure are not widely understood. This review aims to update information on CD45.

Structure of CD45
CD45 is a type 1 transmembrane protein tyrosine phosphatase (PTPase) expressed by all the haematopoietic stem cells (HSCs) except that of erythrocytes and platelets. CD45 is composed of two cytoplasmic domains, a transmembrane domain and an extracellular domain (figure 1). It is a large glycoprotein of 180–220kDa and it forms about 10% of the surface antigens of positively expressing cells. The cytoplasmic domain has a C-terminal tail of 79 amino acids (AAs), a putative wedge-like domain and two tandem PTPase domains. Although both domains are important in the cell physiology, it is only the D1 domain which is enzymatically active. The D2 domain, composed of 19 AAs, can be phosphorylated by C-terminal Src-kinase.

The extracellular portion of the CD45 consists of five regions (figure 1). The extended N-terminal region has alternatively spliced exons, with several regions for O-linked glycosylation and thus form the protein variable area. All species have a similar structure of the CD45 extracellular domain, the three membrane-proximal portion and the type III fibronectin (FnIII) domain. In mammals, between the O-glycan tract and FnIII domains, a globular domain exists with five conserved cysteine-rich domains (figure 1). The CD45 gene, protein tyrosine phosphatase receptor type C (PTPRC), consists of 35 exons, four of which act as alternative mRNA splicing (exons 4, 5, 6 and 7), affecting isoform expression options in different cell types. It is responsible for encoding A, B and C domains (figure 1) leading to the formation of different types of isoforms in the extracellular portion of the CD45 molecule.

Isoforms of CD45
CD45 plays a vital role in HSCs proliferation and differentiation due to the alternative expression of different types of isoforms during their development. Human CD45 mRNA has six isoforms observed with no exon (RO), one exon (RA or RB), two exons (RAB or RBC), or all three exons (RABC) (figure 2).

Encoding various types of CD45 isoforms due to the large number of alternatively spliced transcripts characterised by combinations of 0, 1, 2 or 3 exons, is a feature of CD45 molecule that has been used as a diagnostic tool to distinguish between different types of immune cells. Naïve T cells, for instance, are well known to express CD45RA, while memory and activated T cells express the shortest isoform of CD45, CD45RO (figure 2).

It is the extracellular domain of the CD45 molecule that forms heterogeneity of isoforms by glycosylation and alternative splicing of PTPRC gene exons and is also involved in monitoring the isoform expression by isoform-specific ligand interactions. However, all isoforms possess enzymatic activity and a common structure of Intracellular domain.

It is challenging to define the various functions of variable CD45 isoforms which needs to be elucidated.

CD45 and the innate immune system
In the late eighties and nineties, the role of CD45 on T cell receptor (TCR) and BCR signalling was identified. The effects of CD45 on cytokine, NK receptor and Toll-like receptor (TLR) signalling and

To cite: Al Barashdi MA, Ali A, McMullin MF, et al. J Clin Pathol Epub ahead of print: [please include Day Month Year]. doi:10.1136/jclinpath-2020-206927

© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
CD45: gene polymorphisms and disease consequences

CD45 controls the immune function by regulating lymphocyte survival, cytokine responses, and TCR signalling. Altered CD45 could result in severe combined immunodeficiency (figure 3). Two CD45 polymorphisms have been found in PTPR gene in humans, C77G and A138G. C77G is rare and affects the exon 4 splice silencer, leading to CD45RO isoform deficiency and immune disorders including autoimmune hepatitis, HIV infection and multiple sclerosis. The A138G mutation results in altered CD45 isoform expression with increased numbers of memory activated lymphocytes and increased interferon-gamma production (figure 3).

The A138G polymorphism is found in up to 20% of the Japanese population. It occurs by substitution of exon 6, resulting in elevated production of CD45RO isoform (figure 3). A138G carriers have shown to suffer from Hepatitis B and Graves’ disease. This reflects the association between the increased distributions of this allele in population where these diseases are common.

Abnormal expression of CD45 in leukaemia and lymphoma

CD45 deficiency or altered expression is associated with various diseases including leukaemia and lymphoma. Immunophenotyping studies of CD45 have shown that lymphocytes exhibit the brightest intensity among the other types of leucocytes. This reflects the association between the increased distribution of this allele in population where these diseases are common.

In diffuse large B cell lymphoma, Suzuki et al. have found that interaction between galectin-1 and CD45 glycans could
CD45 expression on non-Hodgkin’s lymphoma cells is higher than found on chronic lymphoblastic leukaemia (CLL) cells. Keeney et al. showed a considerable reduction of CD45 expression in CLL patients associated with an elevated number of smudge cells, a prognostic monitor for disease management. Therefore, determining the CD45 percentages on these cells can be useful to monitor disease development.

Paediatric ALL and Hodgkin lymphoma cells have shown significant disappearance of CD45 expression. Comparison, adult ALL patients with elevated CD45 have shown reduced rate of survival. Patients with high levels of CD45 expression on multiple myeloma cells have shown a favourable prognosis, but cells are more vulnerable to oxidative stress (an apoptotic factor) with activated JAK/STAT pathway initiated by IL-6.

Saint-Paul et al. found that CD45 had a role in the progression of acute myeloid leukaemia (AML), as the disease develops, there is a modification in the position of CD45 within lipid rafts, cholesterol and glycosphingo lipid enriched patches located in the plasma membrane.
Lectins bind to CD45 as well as many other molecules. While CD22 is a lectin B cell surface molecule that inhibits BCR signaling when it binds to CD45, galectin-1 binds and inhibits CD45 PTA, important to enhance T cell apoptosis.30 Furthermore, Galectin-3 binds to glycans on CD45 causing reduction in CD45 PTA which contributes to the pathophysiology of several diseases such as DLBCL,31 heart failure,2 renal fibrosis33 and cancer.34

CD45 antibodies with isoform specificity and selective phosphatase inhibitors have been developed to alter CD45 physiology.35 These are immunosuppressive and used to treat different types of leukemias36 and in stem cell transplantation.37 Development of CD45RB antibodies have been successfully applied in the treatment of modified CD45 isoform expression and prevention of rejection of allografts with associated inflammation caused by allergic pulmonary reactions.37

Alzheimer disease is characterised by the activation of microglial cells which play an essential role in the disease pathophysiology and are highly expressing CD45. Cross-linking of CD45 leads to inactivation of microglial cells.38 It is essential to validate the specificity of CD45 inhibitor to avoid adverse effects considering its wide distribution. Researchers should propose to inhibit the CD45 enzymatic activity, but not the CD45 protein as leukemic cells are highly proliferating and need CD45 activity, while normal cells are resting and do not require CD45 activity. Thus, it would be beneficial to target inhibiting SFK-dependent growth cancer cells to produce high selectivity of CD45 inhibitors. PTP inhibitor XIX (PI-19) is one potential CD45 inhibitor drug used for the treatment of organ graft rejection and autoimmune.19 Perron et al39 discovered 211 (2-[(4-acetylphenyl) amino]-3-chloronaphthoquinone), a selective CD45 inhibitor effective in suppressing T cell responses in a delayed hypersensitivity inflammatory model in vivo with minor toxicity to the normal immune system. This agent could be used as a potential drug to prevent the dissemination of metastasis of lymphoid tumours by targeting CD45 enzymatic activity for cancer therapy.40 This approach would protect normal non-proliferating cells that express CD45 but do not depend on CD45 activity, while clearance of the inhibitor from the body enables normal cells to resume their ability to form new enzymatically active CD45 protein and activate a normal immune response when required.

**SUMMARY**

CD45 is vital for the normal physiology of haematopoiesis. This review has discussed the structure and biological activities of CD45 to better understand the contribution of CD45 to the regulation of the immunity signalling.

**Take home message**

- CD45 has many modes of action including in apoptosis and cell survival. This molecule may be a potentially useful drug target. However, further studies are required to help fully understand all functions of CD45.

**Handling editor** Des Richardson.

**Contributors** As a PhD student at the Queen’s University Belfast, Patrick G Johnston Centre for Cancer Research (PGJCCR); previously known as CCRB, MAAB’s first supervisor, KM provided assistance in reviewing the grammar; second supervisor, MFM participated in the overall revision of content in terms of grammar, paraphrasing and connectivity of sentences. AA is part of our research group as a postdoctoral research fellow helping in figure construction.
REFERENCES

1. Barford D, Flint A, Tonks N. Crystal structure of human protein tyrosine phosphatase CD45. Science 1994;263:1397–404.

2. Rheinländer A, Schraven B, Bomhardt U. CD45 in human physiology and clinical medicine. Immunol Lett 2018;196:22–32.

3. Hermiston ML, Zikherman J, Zhu JW. CD45, CD148, and Lyp/Pep: critical phosphatases regulating Src family kinase signaling networks in immune cells. Immunol Rev 2009;228:288–311.

4. Holmes N. CD45: all is not yet crystal clear. Immunology 2006;117:145–55.

5. Hall LR, Streuli M, Schlosmann SE, et al. Complete exon-intron organization of the human leukocyte common antigen (CD45) gene. J Immunol 1988;141:2781–7.

6. Doman S, Sebestyen Z, Gamble J, et al. Differential association of CD45 isoforms with CD4 and CD8 regulates the activities of specific pools of sP56ck kinase in T cell antigen receptor signal transduction. J Biol Chem 2002;277:1912–8.

7. Hermiston ML, Xu Z, Weiss A. CD45: a critical regulator of signaling thresholds in immune cells. Annu Rev Immunol 2003;21:107–37.

8. Craig W, Poppema S, Little M-T, et al. CD45 isoform expression on human haemopoietic cells at different stages of development. Br J Haematol 1994;88:24–30.

9. Saunders AE, Johnson P. Modulation of immune cell signalling by the leukocyte common tyrosine phosphatase, CD45. Cell Signal 2010;22:339–48.

10. Alexander DR. The CD45 tyrosine phosphatase: a positive and negative regulator of immune cell function. Semin Immunol 2000;12:349–59.

11. Katagiri T, Ogiomo M, Hasegawa K, et al. CD45 negatively regulates Lyn activity by dephosphorylating both positive and negative regulatory tyrosine residues in immature B cells. J Immunol 1999;163:1321–6.

12. Schuette V, Embgenbroich M, Ulas I, et al. Mannose receptor induces T-cell tolerance via inhibition of CD45 and up-regulation of CTLA-4. Proc Natl Acad Sci U S A 2016;113:10649–54.

13. Desharnais P, Dupére-Minier G, Hamelin C, et al. Involvement of CD45 in DNA fragmentation in apoptosis induced by mitochondrial perturbing agents. Apoptosis 2008;13:197–212.

14. Tchilian EZ, Beverley PCL. Altered CD45 expression and disease. Trends Immunol 2006;27:146–53.

15. Shitovic S, Kollet O, Lapid K, et al. CD45 regulates retention, motility, and numbers of hematopoietic progenitors, and affects osteoclast remodeling of metaphyseal trabecules. J Exp Med 2008;205:2381–95.

16. Ron-jun HE, Zhi-hong YU, Ruo-yu Z, et al. Protein tyrosine phosphatases as potential therapeutic targets. Acta Pharmacol Sin 2014;35:1227–46.

17. Boxall S, Stanton T, Hirai K, et al. Disease associations and altered immune function in patients with CD45 deficiency. Hum Mol Genet 2004;13:2377–84.

18. Lynch KW. Consequences of regulated pre-mRNA splicing in the immuncyt system. Nat Rev Immunol 2004;4:931–40.

19. Gitte SJ, Poppema S, Mant MJ, et al. Transition in CD45 isoform expression during differentiation of normal and abnormal B cells. Int Immunol 1989;1:229–36.

20. Suzuki O, Nozawa Y, Abe M. Regulatory roles of altered N- and O-glycosylation of CD45 in galectin-1-induced cell death in human diffuse large B cell lymphoma. Int J Oncol 2005;26:1063–8.

21. Keeney M, Hedley BD, Chin-Yee IH. Flow cytometry-Recognizing unusual populations in leukemia and lymphoma diagnosis. Int J Lab Hematol 2017;39:86–92.

22. Ozdemiril M, Mankin HL, Aisenberg AC, et al. Hodgkin’s disease presenting as a solitary bone tumor: A report of four cases and review of the literature. Cancer 1996;77:79–88.

23. Ratei R, Sperling C, Karawajew L, et al. Immunophenotype and clinical characteristics of CD45-negative and CD45-positive childhood acute lymphoblastic leukemia. Ann Hematol 1998;77:107–14.

24. Ishikawa H, Mahmoud MS, Fujii R, et al. Proliferation of immature myeloma cells by interleukin-6 is associated with CD45 expression in human multiple myeloma. Leuk Lymphoma 2000;39:51–5.

25. Saint-Paul L, Nguyen C-H, Buffière A, et al. CD45 phosphatase is crucial for human and murine acute myeloid leukemia maintenance through its localization in lipid rafts. Oncotarget 2017;8:67485–95.

26. Ebassani GE, Ameers S, Steinbruck L, et al. Expression of the human cytomegalovirus UL11 glycoprotein in viral infection and evaluation of its effect on virus-specific CD8T cells. J Virol 2014;88:14326–39.

27. Gabaei V, Steinbruck L, Pokosky C, et al. The human cytomegalovirus UL11 protein interacts with the receptor tyrosine phosphatase CD45, resulting in functional paralysis of T cells. PLoS Pathog 2011;7:e1002432.

28. Tschirke J, Mamaren P, Pokosky C, et al. The human cytomegalovirus glycoprotein UL11 interacts via CD45 to induce T cell IL-10 secretion. PLoS Pathog 2017;13:e1006455.

29. Julkunen M, Raikar RS, Joshi SG, et al. Placental protein 14 and progestagen-dependent endometrial protein are immunologically indistinguishable. Hum Reprod 1986;1:7–8.

30. Walzel W, Schulz U, Neels P, et al. Galectin-1, a natural ligand for the receptor-type protein tyrosine phosphatase CD45. Immunol Lett 1999;67:193–202.

31. Clark MC, Pang M, Hsu DK, et al. Galectin-3 binds to CD45 on diffuse large B-cell lymphoma cells to regulate susceptibility to cell death. Blood 2012;120:4635–44.

32. Lok DIA, Van Der Meer F de, Pe the Porte PWB-A, et al. Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: data from the DEL-HF study. Clin Res Cardiol 2010;99:323–8.

33. Henderson NC, Mackrinnon AC, Farnworth SL, et al. Galectin-3 expression and secretion links macrophages to the promotion of renal fibrosis. Am J Pathol 2008;172:288–90.

34. Liu F-T, Rabinovich GA. Galectins as modulators of tumour progression. Nat Rev Cancer 2005;5:29–41.

35. Östergaard H, Trowbridge I. Negative regulation of CD45 protein tyrosine phosphatase activity by ionomycin in T cells. Science 1991;253:1423–5.

36. Tschirke J, Mamaren P, Pokosky C, et al. The human cytomegalovirus glycoprotein UL11 acts via CD45 to induce T cell IL-10 secretion. PLoS Pathog 2017;13:e1006455.

37. Zhang Z, Lazarovits A, Gao Z, et al. Prolongation of xenograft survival using monoclonal antibody CD45R8 and cyclophosphamide in RAT-TO-MOUSE kidney and heart transplant MODELS1. Transplantation 2000;69:1137–46.

38. Jen KY, Campo M, He H, et al. CD45RB litigation inhibits allergic pulmonary inflammation by inducing CTLA4 transcription. J Immunol 2007;179:4212–8.

39. Le HT, Cho Y-C, Cho S. Inhibition of protein tyrosine phosphatase non-receptor type 2 by PTP inhibitor XIX: its role as a multiphassthetinhibitor. BMB Rep 2017;50:329–34.

40. Perron N, Saragovi HU. Inhibition of CD45 Protein Phosphatase Activity Induces Cell Cycle Arrest and Apoptosis of CD45+ Lymphoid Tumors Ex Vivo and In Vivo. Mol Pharmacol 2018;93:575–80.

41. Huntington ND, Xu Y, Nutt SL, et al. A requirement for CD45 distinguishes Ly49D-mediated cytokine and chemokine production from killing in primary natural killer cells. J Exp Med 2005;201:1421–33.

42. Wu L, Bijian K, Shen S-S. CD45 recruits adapter protein Dok-1 and negatively regulates JAK1–STAT signaling in hematopoietic cells. Mol Immunol 2009;46:2167–77.

43. Cale CM, Klein NJ, Novelli V. Severe combined immunodeficiency with abnormalities in expression of the common leucocyte. J Clin Pathol 2018;71:39–47.

44. Eric L, Desoz EL, Danet K, et al. CD45 negatively regulates monocyct cell differentiation by inhibiting phorbol 12-myristate 13-acetate-dependent activation and tyrosine phosphorylation of protein kinase. J Biol Chem 2001;276:10212–7.

45. Kreisinsky A, Schröder TM, Jacobsen ID, et al. Lack of CD45 in FL3-TID mt cells results in a myeloproliferative phenotype, cortical porosity, and ectopic bone formation. Oncogene 2013:28:4773–81.